Literature DB >> 23934601

Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome.

Marry H Nieuwenhuis1, C Marleen Kets, Maureen Murphy-Ryan, Helger G Yntema, D Gareth Evans, Chrystelle Colas, Pal Møller, Frederik J Hes, Shirley V Hodgson, Maran J W Olderode-Berends, Stefan Aretz, Karl Heinimann, Encarna B Gómez García, Fiona Douglas, Allan Spigelman, Susanne Timshel, Noralane M Lindor, Hans F A Vasen.   

Abstract

Patients with germline PTEN mutations are at high risk of developing benign and malignant tumours. We aimed to evaluate the cumulative risk of several types of cancer and of dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease, LDD). In addition, genotype-phenotype correlations in PTEN hamartoma tumour syndrome (PHTS) were assessed. Data on patients with PTEN mutations were collected from clinical genetic centres in Western Europe, Australia, and the USA. The cumulative risk of developing cancers of the breast, thyroid, endometrium, skin, kidneys, colorectum, and lungs, and also LDD was calculated by Kaplan-Meier methods. Associations between mutations and cancer were assessed by Chi square means. A total of 180 germline PTEN mutation carriers, 81 males (45%), from nine countries were included. The cumulative risk of developing any cancer and/or LDD at age 60 was 56% for males and 87% for females (p = 0.001). Females had significant higher risks of developing breast cancer, thyroid cancer, and LDD than males. The only genotype-phenotype correlation identified was a lower frequency of thyroid cancer in patients with missense mutations (p = 0.014). In conclusion, PHTS patients, particularly females, have a substantial risk of developing one or more tumours from a broad tumour spectrum. Major genotype-phenotype associations could not be identified.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23934601     DOI: 10.1007/s10689-013-9674-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  18 in total

Review 1.  PI(3)king apart PTEN's role in cancer.

Authors:  Siyuan Zhang; Dihua Yu
Journal:  Clin Cancer Res       Date:  2010-07-08       Impact factor: 12.531

2.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Authors:  Min-Han Tan; Jessica Mester; Charissa Peterson; Yiran Yang; Jin-Lian Chen; Lisa A Rybicki; Kresimira Milas; Holly Pederson; Berna Remzi; Mohammed S Orloff; Charis Eng
Journal:  Am J Hum Genet       Date:  2010-12-30       Impact factor: 11.025

Review 3.  Mutations of the human PTEN gene.

Authors:  D Bonneau; M Longy
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

4.  Subtle variations in Pten dose determine cancer susceptibility.

Authors:  Andrea Alimonti; Arkaitz Carracedo; John G Clohessy; Lloyd C Trotman; Caterina Nardella; Ainara Egia; Leonardo Salmena; Katia Sampieri; William J Haveman; Edi Brogi; Andrea L Richardson; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

5.  Allele-specific tumor spectrum in pten knockin mice.

Authors:  Hui Wang; Matt Karikomi; Shan Naidu; Ravi Rajmohan; Enrico Caserta; Hui-Zi Chen; Maysoon Rawahneh; Julie Moffitt; Julie A Stephens; Soledad A Fernandez; Michael Weinstein; Danxin Wang; Wolfgang Sadee; Krista La Perle; Paul Stromberg; Thomas J Rosol; Charis Eng; Michael C Ostrowski; Gustavo Leone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

6.  Brain magnetic resonance imaging in patients with Cowden syndrome.

Authors:  Catherine Lok; Valérie Viseux; Marie Françoise Avril; Marie Aleth Richard; Catherine Gondry-Jouet; Hervé Deramond; Caroline Desfossez-Tribout; Sandrine Courtade; Michèle Delaunay; Fréderic Piette; Daniel Legars; Brigitte Dreno; Philippe Saïag; Michel Longy; Gérard Lorette; Liliane Laroche; Fréderic Caux
Journal:  Medicine (Baltimore)       Date:  2005-03       Impact factor: 1.889

Review 7.  Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.

Authors:  M S Orloff; C Eng
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

Review 8.  PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development.

Authors:  Jaclyn Lopiccolo; Marc S Ballas; Phillip A Dennis
Journal:  Crit Rev Oncol Hematol       Date:  2007-07-20       Impact factor: 6.312

9.  Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers.

Authors:  K L Lachlan; A M Lucassen; D Bunyan; I K Temple
Journal:  J Med Genet       Date:  2007-05-25       Impact factor: 6.318

10.  Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients.

Authors:  Douglas L Riegert-Johnson; Ferga C Gleeson; Maegan Roberts; Krysta Tholen; Lauren Youngborg; Melvin Bullock; Lisa A Boardman
Journal:  Hered Cancer Clin Pract       Date:  2010-06-17       Impact factor: 2.857

View more
  28 in total

1.  Rare Coding Variants Associated with Breast Cancer.

Authors:  Mi-Ryung Han
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Clinical management of hereditary colorectal cancer syndromes.

Authors:  Hans F A Vasen; Ian Tomlinson; Antoni Castells
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-13       Impact factor: 46.802

3.  PTEN modulates gene transcription by redistributing genome-wide RNA polymerase II occupancy.

Authors:  Ata Abbas; Roshan Padmanabhan; Todd Romigh; Charis Eng
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

4.  PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation?

Authors:  Lamis Yehia; Charis Eng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 5.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  PTEN-opathies: from biological insights to evidence-based precision medicine.

Authors:  Lamis Yehia; Joanne Ngeow; Charis Eng
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

7.  Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations.

Authors:  Scott K Sherman; Jessica E Maxwell; Qining Qian; Andrew M Bellizzi; Terry A Braun; Mark D Iannettoni; Benjamin W Darbro; James R Howe
Journal:  Cancer Genet       Date:  2014-11-15

Review 8.  Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.

Authors:  Amanda B Spurdle; Michael A Bowman; Jannah Shamsani; Judy Kirk
Journal:  Mod Pathol       Date:  2017-04-28       Impact factor: 7.842

9.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Authors:  Joanne Ngeow; Kim Stanuch; Jessica L Mester; Jill S Barnholtz-Sloan; Charis Eng
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

10.  Molecular biology of gynecological cancer.

Authors:  Kenzo Sonoda
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.